When one realizes that revenue is increasing but gross margin is declining, it becomes clear that managing a pharmacy is no longer just about buying well and selling well. Pharmacy management in 2026 requires monitoring finer indicators, reallocating human resources differently, and rethinking profitability by product family. Here are the concrete levers that make a difference at the counter as well as in the back office.
Margin by product family: the dashboard that most pharmacies lack
Most pharmacy management software displays an overall margin. In practice, this single figure masks significant discrepancies between families. Reimbursable medications at regulated prices generate a capped margin that contracts year after year, while over-the-counter products or medical devices can yield significantly higher margins, provided that purchases and pricing are managed on a case-by-case basis.
It is beneficial to segment the margin by family each month rather than relying on the annual gross margin rate. This analysis allows for the identification of references that weigh on profitability and those that enhance it. The Fiducial Observatory 2026 confirms this trend: average revenue excluding taxes is increasing, but average gross margin is declining due to price reductions on reimbursable medications and the growing weight of high-cost products with capped margins.
Specifically, one can structure monitoring into three columns that guide purchasing decisions, promotional operations, and shelf facing adjustments. The resources available on pharmazenconseil.fr detail segmentation methods tailored to the real constraints of an independent pharmacy.
New public health missions: organizing time before counting actions
Vaccinations, rapid diagnostic tests, pharmaceutical consultations, colorectal cancer screening: pharmacists performed more public health missions in 2025 than in 2024 according to IQVIA Pharmastat data. The natural reflex is to multiply actions to compensate for the erosion of margins on medications. In practice, without prior organization, these missions disrupt the counter and exhaust the team.
Three constraints to resolve before launching a new mission
- The schedule: each mission requires a pharmacist for an unmovable time slot. Blocking dedicated time slots rather than interspersing actions between two prescriptions avoids cascading delays at the counter.
- Confidentiality space: a pharmaceutical consultation or rapid diagnostic test requires a closed space. If the pharmacy has only one room, it cannot schedule two missions in parallel, which mechanically limits the achievable volume.
- Training: a trained pharmacy technician for screening frees up pharmacist time for actions that require a diploma. Investing in the training of technicians multiplies operational capacity without additional hiring.
Measuring the actual time spent on each mission, even approximately over a few weeks, allows for calculating an internal hourly cost. This cost, compared to the remuneration of the action, gives the net profitability of the mission. Some missions turn out to be unprofitable if the flow at the counter is disrupted; feedback on this varies depending on the size of the pharmacy and the layout of the premises.
Cash flow and operating expenses: managing real profitability
Profitability in pharmacy is often discussed in terms of margin rate. Cash flow tells a different story. A pharmacy can show a decent margin while accumulating delays on supplier payments because the gap between social security reimbursements and wholesaler payments creates a permanent working capital need.
Two expense items deserve close monitoring:
Payroll and revenue per employee ratio
Payroll is the largest expense item in most pharmacies. The revenue per employee ratio provides a direct reading of productivity. When this ratio stagnates while new missions increase, it actually finances unpaid activity to the detriment of the counter.
Adjusting schedules based on peak traffic times (weekday mornings, Saturday mornings) and mission slots allows for distributing the workload without increasing payroll. A simple attendance record over two weeks is enough to identify underutilized time slots.
Purchases and supplier conditions
Renegotiating purchasing conditions once a year is no longer sufficient. Regular price reductions on generics change discount thresholds throughout the year. One can request a quarterly report from their wholesaler on the conditions applied and compare it to the direct manufacturer price when the volume justifies it.
Structural fee and economic model reform: what is taking shape
An IGAS-IGF report has outlined the possibility of a structural fee that would complement remuneration based on actions and margins. The idea is to compensate the pharmacy for its capacity to accommodate, its territorial network, and its equipment, regardless of the volume of boxes sold.
Neither amount nor timeline is set at this stage. But this direction indicates a clear trend: future profitability will depend as much on organization as on volume. Pharmacies that already document their fixed costs, mission time, and capacity to accommodate will be better positioned if such a fee comes into effect.
For rural pharmacies or those located in under-served areas, this reform could partially offset the fragility associated with a low volume of prescriptions. Anticipating by structuring a follow-up on fixed costs and operational capacity remains the best preparation, regardless of the final form of the system.
Pharmacy management is no longer just about an annual balance sheet reviewed with an accountant. Monitoring the margin by family each month, measuring the real cost of new missions, and continuously monitoring cash flow are three practices that protect profitability in an environment where prices are falling but responsibilities are increasing.
